Tuberculosis Molecular Diagnostics — iFIND TBR + IFQ

Overview

Tuberculosis remains one of the largest infectious-disease burdens worldwide, and drug-resistant tuberculosis complicates treatment in many regions. The iFIND molecular diagnostics platform, manufactured in China, is presented here as a candidate solution for rapid TB detection and drug-resistance profiling.

This page summarises the solution for a global audience. Market-specific guidance for Russia and India is published separately under each market.

The Global TB Problem

Tuberculosis is caused by bacteria of the Mycobacterium tuberculosis complex. The key diagnostic challenges are:

1. Rapid detection of the M. tuberculosis complex.
2. Drug-resistance detection, beginning with rifampicin resistance — the principal marker of multidrug-resistant TB (MDR-TB) — and extending to isoniazid and fluoroquinolone resistance.

Fast molecular detection of TB and its drug-resistance markers allows earlier, more appropriate treatment, which is critical for both individual outcomes and public-health control.

The Chinese Solution Scope: iFIND TBR + IFQ

The iFIND platform is an automated molecular diagnostics system with random-access capability and closed microfluidic cartridges. It is available in three configurations:

Two reagent kits address TB and its drug resistance:

iFIND TBR — TB detection + rifampicin resistance

• Detects the M. tuberculosis complex and rifampicin resistance.
• Amplification targets: IS6110, IS1081 / IS1087 (manufacturer documents disagree — see conflict note), and rpoB.
• Manufacturer-stated limit of detection: 10 CFU/mL for TB detection; 100 CFU/mL for rifampicin resistance.
• Manufacturer-stated turnaround time: 85 minutes in one source and 120 minutes in another — this discrepancy is documented and unresolved.

iFIND IFQ — isoniazid + fluoroquinolone resistance

• Detects mutations associated with resistance to isoniazid and fluoroquinolones.
• Amplification targets: katG, inhA, gyrA.
• Manufacturer-stated limit of detection: 100 CFU/mL.
• Manufacturer-stated turnaround time: 120 minutes.
• Does not detect resistance to injectable drugs (amikacin, kanamycin, capreomycin).

Sequential use of TBR followed by IFQ produces an expanded resistance profile covering rifampicin, isoniazid, and fluoroquinolones.

Evidence Boundary

All technical parameters above are manufacturer-provided. The available evidence is limited to manufacturer brochures, technical specification sheets, and instructions for use — evidence level B.

• No independent peer-reviewed clinical studies have been confirmed.
• No multicentre trial data is available.
• Two conflicts in the manufacturer documentation are documented and unresolved: the IS1081 / IS1087 target discrepancy and the 85-minute versus 120-minute turnaround-time discrepancy.
• Independent clinical sensitivity and specificity have not been confirmed.

Local Implementation Gap

Before the iFIND platform can be used clinically in any target market, several market-specific steps remain:

• Regulatory registration must be confirmed for the specific market. For Russia this means Roszdravnadzor registration; for India this means CDSCO registration. Both are currently "not verified".
• Local service and support, including a service network and consumables supply chain, must be established.
• Local validation on the local sample population must be performed by each laboratory.
• Documentation in the local language (Russian; Hindi or English for India) is required.

Important Constraints

• No FDA, WHO, Roszdravnadzor, or CDSCO approval is claimed or implied.
• The platform is not offered for sale on this platform. SinoBio Access is not a distributor.
• All claims are labelled with their evidence level and claim status. See Evidence Policy and How We Work for details.

For market-specific evaluation guidance, see the Russia and India sections.